[HTML][HTML] A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications …

AN Nowbar, C Rajkumar, M Foley… - …, 2022 - ncbi.nlm.nih.gov
Percutaneous coronary intervention (PCI) is frequently performed for stable angina.
However, the first blinded trial, ORBITA, did not show a placebo-controlled increment in …

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

R Al-Lamee, D Thompson, HM Dehbi, S Sen, K Tang… - The Lancet, 2018 - thelancet.com
Background Symptomatic relief is the primary goal of percutaneous coronary intervention
(PCI) in stable angina and is commonly observed clinically. However, there is no evidence …

Quality of life assessment in trials of revascularization for chronic stable angina: insights from ORBITA and the implications of blinding

AN Nowbar, DP Francis, RK Al-Lamee - Cardiovascular drugs and therapy, 2022 - Springer
The main aims of therapy in chronic stable angina are to reduce the risk of myocardial
infarction and death and improve symptoms and quality of life (QoL). Unblinded trials have …

[HTML][HTML] A placebo-controlled trial of percutaneous coronary intervention for stable angina

CA Rajkumar, MJ Foley, F Ahmed-Jushuf… - … England Journal of …, 2023 - Mass Medical Soc
Background Percutaneous coronary intervention (PCI) is frequently performed to reduce the
symptoms of stable angina. Whether PCI relieves angina more than a placebo procedure in …

Achieving optimal medical therapy: insights from the ORBITA trial

M Foley, CA Rajkumar, M Shun‐Shin… - Journal of the …, 2021 - Am Heart Assoc
Background In stable coronary artery disease, medications are used for 2 purposes:
cardiovascular risk reduction and symptom improvement. In clinical trials and clinical …

Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon

A Spirito, D Cao, R Mehran - European Heart Journal, 2022 - academic.oup.com
In recent years, new evidence redefined the role of coronary revascularization in the
management of patients with chronic coronary syndrome (CCS). The primacy of coronary …

COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease.

Z Teoh, RK Al-Lamee - Interventional Cardiology Clinics, 2020 - europepmc.org
This review article summarizes key landmark trials that have shaped understanding of the
role of percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD) …

Symptoms as a predictor of the placebo-controlled efficacy of PCI in stable coronary artery disease

FA Simader, CA Rajkumar, MJ Foley… - Journal of the American …, 2024 - Elsevier
Background Placebo–controlled evidence from ORBITA-2 found that percutaneous
cutaneous intervention (PCI) in stable coronary artery disease with little or no antianginal …

Rates of elective percutaneous coronary intervention in England and Wales: impact of courage and ORBITA trials

M Rashid, C Stevens, HC Wijeysundera… - Journal of the …, 2022 - Am Heart Assoc
Background There are limited data about how COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) and ORBITA (Objective Randomized …

Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?

DHJ Elder, M Pauriah, CC Lang, J Shand… - … Journal of Medicine, 2010 - academic.oup.com
Background: In the management of chronic stable angina, percutaneous coronary
intervention (PCI) provides symptomatic relief of angina rather than improvement of …